Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
NCT07707674 XNW-28012 Metastatic Pancreatic Cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07707674 XNW-28012 Metastatic Pancreatic Cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
NCT07707674 clinical trial report covering XNW-28012, Phase 1, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07714798 Universal STAR-T Cell(BriSTAR Immunotech) Myasthenia Gravis Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07714798 Universal STAR-T Cell(BriSTAR Immunotech) Myasthenia Gravis Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
NCT07714798 clinical trial report covering Universal STAR-T Cell(BriSTAR Immunotech), Phase 1, endpoints, sponsor, geography, readout timing and developmen
Read →
NCT07717086 HYR-PB21 Pain, Postoperative Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07717086 HYR-PB21 Pain, Postoperative Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
NCT07717086 clinical trial report covering HYR-PB21, Phase 1, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07719088 Psilocybin disorder of aging Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07719088 Psilocybin disorder of aging Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
NCT07719088 clinical trial report covering Psilocybin, Phase 1, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07615660 Bulumtatug fuvedotin Advanced Malignant Solid Neoplasm Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07615660 Bulumtatug fuvedotin Advanced Malignant Solid Neoplasm Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
NCT07615660 clinical trial report covering Bulumtatug fuvedotin, Phase 1/2, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07612891 INV-6452 Locally Advanced Malignant Solid Neoplasm Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07612891 INV-6452 Locally Advanced Malignant Solid Neoplasm Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
NCT07612891 clinical trial report covering INV-6452, Phase 1/2, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07615283 Zeprumetostat Peripheral T-Cell Lymphoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07615283 Zeprumetostat Peripheral T-Cell Lymphoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
NCT07615283 clinical trial report covering Zeprumetostat, Phase 1/2, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07612787 ALK.CAR-T cells(University of Turin/Boston Children) Relapse multiple myeloma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07612787 ALK.CAR-T cells(University of Turin/Boston Children) Relapse multiple myeloma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
NCT07612787 clinical trial report covering ALK.CAR-T cells(University of Turin/Boston Children), Phase 1/2, endpoints, sponsor, geography, readout timing a
Read →
NCT07615881 Ipilimumab Melanoma, Cutaneous Malignant Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07615881 Ipilimumab Melanoma, Cutaneous Malignant Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
NCT07615881 clinical trial report covering Ipilimumab, Phase 1/2, endpoints, sponsor, geography, readout timing and development white space.
Read →
ChiCTR2600125907 Umbilical Cord Mesenchymal Stem Cell Exosomes(Sixth Affiliated Hospital, Sun Yat Anemia, Aplastic Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
ChiCTR2600125907 Umbilical Cord Mesenchymal Stem Cell Exosomes(Sixth Affiliated Hospital, Sun Yat Anemia, Aplastic Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
ChiCTR2600125907 clinical trial report covering Umbilical Cord Mesenchymal Stem Cell Exosomes(Sixth Affiliated Hospital, Sun Yat, Phase 1/2, endpoints, spo
Read →
NCT07617805 Fludarabine Phosphate Squamous cell carcinoma of head and neck metastatic Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07617805 Fludarabine Phosphate Squamous cell carcinoma of head and neck metastatic Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
NCT07617805 clinical trial report covering Fludarabine Phosphate, Phase 1/2, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07618195 EPI-001(Epi Biotech) Androgenetic Alopecia Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07618195 EPI-001(Epi Biotech) Androgenetic Alopecia Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
NCT07618195 clinical trial report covering EPI-001(Epi Biotech), Phase 1/2, endpoints, sponsor, geography, readout timing and development white space.
Read →